Background
==========

It is known that inherited genomic CNV is linked to risk for human disease and response to treatment. It has also been established for decades that genomic variation, including CNV in germline DNA, can help predict variation in efficacy and/or adverse responses to therapeutic drugs \[[@B1]-[@B5]\]. For example, individuals with multiple copies of the gene encoding the drug metabolizing enzyme CYP2D6 are \"ultrarapid\" metabolizers as compared to those with *CYP2D6*deletions (\"poor\" metabolizers), and these genotypes are associated with variation in response to a large number of drugs \[[@B4],[@B6]\]. CNVs within the human genome are not rare events. Redon et. al. \[[@B7]\] identified nearly 1,500 CNV regions scattered throughout the genome in 270 HapMap samples. Those regions comprised approximately 10% of the human genome, encompassing coding and non-coding regions, as compared to the \< 1% of the genome that is occupied by SNPs \[[@B8]\]. CNVs appear to be present at lower frequencies than SNPs \[[@B9]\], but this may be due in part to the techniques utilized to identify them. Thus, the prevalence and biological significance of CNVs may be underestimated. As of early 2009, nearly 6,225 CNV loci had been cataloged by the Database of Genomic Variants <http://projects.tcag.ca/variation/>. In addition, nearly 18% of mRNA species that are genetically regulated through *cis*effects could be explained by CNVs \[[@B10]\]. Together with SNP genotypes, CNV data can be generated with SNP arrays \[[@B7],[@B9],[@B11]-[@B13]\]. Although these methodologies have limitations \[[@B14]\], CNVs, depending on their size and location, may be just as important for variation in function as are SNPs.

The cytidine analogues, gemcitabine and AraC, show significant therapeutic effect in several types of cancer. Gemcitabine is mainly used to treat solid tumors \[[@B15],[@B16]\] while AraC is used to treat acute myelogenous leukemia \[[@B17]\]. Clinical response to these two drugs varies widely, and previous studies showed that inheritance can contribute to the variation in response of these two drugs \[[@B18]\]. In this study, we set out to test the hypothesis that CNV might contribute to variation in gemcitabine and AraC response in 197 EBV transformed lymphoblastoid cell lines using SNP data obtained with Illumina 550 and 650 K SNP arrays.

Methods
=======

Genotyping and populations
--------------------------

A subset of the \"Human Variation Panel\" lymphoblastoid cell lines consisting of 60 Caucasian-American (CA), 54 African-American (AA), and 60 Han Chinese-American (HCA), as well as 23 CEPH Caucasian HapMap EBV transformed cell lines was obtained from the Coriell Cell Repository (Camden, NJ). These cell lines had been obtained from healthy individuals and were anonymized by the National Institute of General Medical Sciences prior to deposit. All of these individuals had provided written consent for the use of their cells and DNA from those cells to be used for experimental purposes. We genotyped the AA DNA from these cell lines using the Illumina Human Hap 650 beadchip (Human660W-Quad v1), and the Illumina Human Hap 550 beadchips were used to genotype the remainder of the samples. All samples were genotyped in the Mayo Clinic Genotyping Core Facility. All but two samples had a call rate greater than 98%, and those two samples, even after repetition, had call rates between 95 and 98%. We assessed LRR standard deviation (SD) for our samples and found that none of the samples had a SD less than 0.21. Quality control (QC) recommendations for the PennCNV or QuantiSNP algorithms suggest using a SD \< 0.3 \[[@B19]\]. Since, our LRR standard deviation did not exceed this QC threshold; we also used those two samples in the analysis. For consistency, we did not include the additional 100 K SNPs genotyped for the AA samples in the CNV analysis.

Copy number identification
--------------------------

Bead Studio version 3.1 was used to obtain log R ratios and B allele frequencies for 550,000 SNPs in the 197 samples studied. LogR ratios were generated by comparing our experimental LogR values to Bead Studio\'s built in multi-ethnic HapMap population. CNV genotyping was performed using an Objective Bayes Hidden-Markov model (QuantiSNP) \[[@B20]\] plug-in within Illumina\'s Bead Studio interface. QuantiSNP is a statistical algorithm that utilizes joint information with regard to log R ratios and B allele frequencies for quantitative SNP array data analysis that allows for precise discovery and mapping of copy number changes. We used the QuantiSNP parameters recommended by Illumina: expectation maximization = 10, CNV length = 10,000, maximum copy number returned = 4, no GC content normalization, and score threshold = 50. After applying the QuantiSNP algorithm, we exported the CNV values and confidence values for each SNP out of the Bead Studio software. Using our own in-house programs written in R and Perl, we then separated all SNPs associated with CNVs that were observed in two or more samples (frequency \> 1%). These thresholds and parameters were set conservatively to accurately identify CNVs under these conditions. This approach should reduce the false positive rate, but at the risk of increasing the false negative rate and missing more common, yet smaller CNVs that are inherently more difficult to detect. After transforming CNV values for each SNP into deletion (CNV value \< 2), normal (CNV value = 2) or amplification (CNV value \> 2), distinct copy number regions were obtained by merging neighboring SNPs with identical CNVs across samples. A detailed description of the methods used is available in the Additional file [1](#S1){ref-type="supplementary-material"} Methods Section.

Copy number validation
----------------------

Eleven copy number regions found to be associated with gemcitabine and AraC IC~50~values (p \< 0.05) were selected for validation using multiplex ligation-dependent probe amplification (MLPA). Oligonucleotides were preferentially designed based on a successful assay, followed by selection for coding sequences and underlying p-values. M13 sequence was attached to each probe together with a complementary FlexMap100 sequence (Luminex, Austin, TX). Specifically, 80 ng of DNA was denatured at 98°C for 5 minutes, followed by 25°C for 1 minute. In an 8 μL reaction, 80 ng of DNA and 0.3 femtomole/μL of each probe were mixed with 1.5 μL of MLPA buffer (MRC-Holland, Amsterdam, Netherlands). Probes were allowed to hybridize at 60°C for 16-24 hours. Probes were ligated in a reaction containing 25 μl H~2~O, 3 μL Ligase-65 Buffer A and B (MRC-Holland), and 1 μL Ligase-65 (MRC-Holland) at 54°C for 15 minutes, followed by 98°C for 5 minutes. Each 50 μL PCR reaction consisted of 10 μL of ligated product mixed with 27.5 μL H~2~O, 5 μL 10 × buffer (Invitrogen, Carlsbad, CA), 1.5 μL 50 mM MgCl~2~(Invitrogen), 4 μL 10 mM dNTPs (Applied Biosystems, Foster City, CA), 0.5 μL 10 μM M13 primers, and 1 μL Platinum Taq (Invitrogen). 10 μL of PCR product was then added to 40 μL of bead mix containing 2,000 beads for each FlexMap Microsphere (Luminex) suspended in 1 × TMAC, and the mixture was incubated at 96°C for 2 minutes, followed by 37°C for 60 minutes. Following incubation, 0.2 μL of Streptavidin R-Phycoerythrin Conjugate (Invitrogen) plus 25 μL of 1 × TMAC was added and incubated at room temperature for 30 minutes. Samples were assayed on a LiquiChip 100IS System (Qiagen, Valencia, CA) and results were analyzed with GeneMarker 1.6 software. Of the 11 CNV assayed, one (chr14CNV87:106047919-106066496), did not provide adequate signal intensity for analysis.

MTS assay
---------

AraC was purchased from Sigma-Aldrich (St. Louis, MO) and gemcitabine was provided by Eli Lilly (Indianapolis, IN). Cytotoxicity assays were performed with the CellTiter 96^®^Aqueous Non-Radioactive Cell Proliferation Assay (Promega Corporation, Madison, WI). The drug concentrations used to perform these experiments were described in detail previously by Li et al., 2008 \[[@B18]\].

Statistical analysis
--------------------

The cytotoxicity phenotype (IC~50~) was determined on the basis of the best fitting curve, either 4 parameter logistic, 4 parameter logistic with top = 100%, or 4 parameter logistic with bottom = 0%. The curves were constructed using the dose response curves package in R. The logistic model with the lowest mean square error was used to determine IC~50~values for gemcitabine and AraC as described in Li et al. \[[@B18]\]. Drug response phenotypes (IC~50~values) for both drugs were adjusted for ethnicity, gender and storage time of the 197 samples using linear regression (natural log transformation applied to IC~50~values). In addition, CNV values were adjusted for ethnicity and gender. Linear regression was then used to perform association with adjusted CNV values (residuals from regressing CNV against ethnicity and gender) with adjusted IC~50~phenotypes (residuals from regressing log IC~50~against ethnicity, gender and storage time). P-values for association were obtained after performing 1000 permutations for both gemcitabine and AraC IC~50~values.

Transient transfection and RNA interference
-------------------------------------------

Human MiaPaca-2 pancreatic cancer cells were transfected with siRNA using Lipofectamine RNAMAX (Invitrogen). Specifically, cells were seeded into 96-well plates and were mixed with siRNA-complex containing 50 nM specific or negative control siRNA (Qiagen) and transfection reagent (Invitrogen) in Opti-MEM^®^I Reduced Serum Media (Invitrogen). Forty eight hours post-transfection, cells were harvested for cell-based assays. SMYD3 siRNA and negative control siRNA were purchased from Qiagen and were used as suggested by the manufacturer.

Sequences for siRNA against SMYD3 were: Sense strand: GGC GAU CAU AAG CAG CAA UdTdT CGA UUA UAA UAA AUU CAA CdTdT

Antisense strand: AUU GCU GCU UAU GAU CGC CdTdT UUU GAA UUU AUU AUA AUC GdTdG

Sequences for negative control siRNA were:

Sense strand: UUC UCC GAA CGU GUC ACG UdTdT

Antisense strand: ACG UGA CAC GUU CGG AGA AdTdT

Real-time quantitative reverse transcription-PCR
------------------------------------------------

Total RNA was isolated from cultured cells with the Qiagen RNeasy kit (Qiagen), followed by QRT-PCR performed with the 1-step, Brilliant II SYBR Green QRT-PCR master mix kit (Stratagene, La Jolla, CA). Specifically, primers purchased from Qiagen were used to perform QRT-PCR using the Stratagene Mx3005P™ Real-Time PCR detection system (Stratagene). All experiments were performed in triplicate with β-actin as an internal control. Control reactions lacked RNA template.

Results
=======

CNV identification
------------------

We used the QuantiSNP parameters recommended by Illumina for copy number identification. The QuantiSNP algorithm in Illumina provided CNV values and confidence values for each SNP and sample. After pre-processing the data, we had 73,738 SNPs with CNV values other than \"normal\" (CNV value = 2). 1,674 SNPs were retained in the analysis after excluding SNPs that did not display variation in at least two samples (minor allele frequency \> 1%). We then applied a simple segregation algorithm as described in Additional file [1](#S1){ref-type="supplementary-material"} Methods and identified 775 CNVs at 102 loci using the 197 DNA samples obtained from 3 ethnic groups. Figure [1](#F1){ref-type="fig"} shows the CNV call results using CNV region display in Bead Studio Software for 15 samples selected randomly from among the 197 samples assayed. From the randomly selected data displayed in Figure [1](#F1){ref-type="fig"}, it is clear that specific CNV regions could be associated with multiple DNA samples. Copy number loci or regions can also have multiple forms of variation, probably as a result of different breakpoints. The mean and median CNV frequencies per sample were 3.9 and 4.0, respectively, with a maximum value of 10. The 102 CNV loci identified represented 7.8 Mb of sequence, with an average length of 77 kb and a median of 20 kb (90 bp to 1.7 Mb) (Table [1](#T1){ref-type="table"}). Twenty five CNVs identified in this study were observed in all three ethnic groups; 45 CNVs were found in 2 ethnicities; and 32 CNVs were observed in only one ethnic group (Table [1](#T1){ref-type="table"}). No loci below 1% copy number frequency were reported in this study.

###### 

CNV regions identified in 197 DNA samples.

  CNV_ID        Start       Stop        Size      AA      CA      HCA     Combined CNV Frequency
  ------------- ----------- ----------- --------- ------- ------- ------- ------------------------
  chr1CNV1      12789177    12834675    45498     0.036   0.024   0.050   0.035
                                                                          
  chr1CNV2      94906770    94925850    19080     0.091   0.000   0.000   0.025
                                                                          
  chr1CNV3      105966892   106000090   33198     0.055   0.000   0.017   0.020
                                                                          
  chr1CNV4      147306690   147414362   107672    0.036   0.012   0.000   0.015
                                                                          
  chr1CNV5      187665261   187809352   144091    0.000   0.000   0.083   0.025
                                                                          
  chr1CNV6      195092486   195160949   68463     0.073   0.000   0.083   0.045
                                                                          
  chr1CNV7      243707190   243713984   6794      0.000   0.036   0.000   0.015
                                                                          
  chr2CNV8      41092376    41099005    6629      0.273   0.024   0.017   0.091
                                                                          
  chr2CNV9      57281457    57295357    13900     0.000   0.036   0.000   0.015
                                                                          
  chr2CNV10     89397452    89877778    480326    0.036   0.060   0.017   0.040
                                                                          
  chr2CNV11     110228954   110315618   86664     0.036   0.012   0.050   0.030
                                                                          
  chr2CNV12     184808081   184866619   58538     0.127   0.012   0.000   0.040
                                                                          
  chr2CNV13     242566407   242653950   87543     0.000   0.084   0.000   0.035
                                                                          
  chr3CNV14     6194326     6211038     16712     0.073   0.000   0.000   0.020
                                                                          
  chr3CNV15     53003415    53010084    6669      0.000   0.048   0.017   0.025
                                                                          
  chr3CNV16     65168286    65187636    19350     0.018   0.120   0.117   0.091
                                                                          
  chr3CNV17     75535790    75610832    75042     0.000   0.036   0.000   0.015
                                                                          
  chr3CNV18     101837214   101854561   17347     0.000   0.036   0.000   0.015
                                                                          
  chr3CNV19     152997395   153028291   30896     0.000   0.036   0.000   0.015
                                                                          
  chr3CNV20     163614102   163617940   3838      0.018   0.060   0.000   0.030
                                                                          
  chr3CNV21     163701543   163710564   9021      0.000   0.012   0.283   0.091
                                                                          
  chr3CNV22     166750382   166766442   16060     0.036   0.012   0.000   0.015
                                                                          
  chr3CNV23     177371924   177397828   25904     0.000   0.072   0.000   0.030
                                                                          
  chr3CNV24     189070613   189088009   17396     0.000   0.012   0.033   0.015
                                                                          
  chr3CNV25     192548615   192550982   2367      0.000   0.120   0.000   0.051
                                                                          
  chr4CNV26     64386888    64391664    4776      0.000   0.024   0.033   0.020
                                                                          
  chr4CNV27     64780488    64795145    14657     0.000   0.000   0.050   0.015
                                                                          
  chr4CNV28     88405746    88445557    39811     0.055   0.000   0.000   0.015
                                                                          
  chr4CNV29     104433739   104454829   21090     0.091   0.000   0.000   0.025
                                                                          
  chr4CNV30     161277505   161290832   13327     0.000   0.060   0.000   0.025
                                                                          
  chr4CNV31     162083578   162175279   91701     0.000   0.012   0.083   0.030
                                                                          
  chr5CNV32     9955403     9976731     21328     0.036   0.036   0.000   0.025
                                                                          
  chr5CNV33     97075236    97107276    32040     0.036   0.036   0.000   0.025
                                                                          
  chr5CNV34     117418457   117420311   1854      0.109   0.060   0.000   0.056
                                                                          
  chr5CNV35     120337992   120440119   102127    0.055   0.000   0.000   0.015
                                                                          
  chr5CNV36     160474752   160479606   4854      0.000   0.000   0.050   0.015
                                                                          
  chr2CNV37     67076651    67104015    27364     0.018   0.181   0.000   0.081
                                                                          
  chr6CNV38     79031111    79086086    54975     0.255   0.410   0.083   0.268
                                                                          
  chr6CNV39     93632051    93634213    2162      0.073   0.000   0.017   0.025
                                                                          
  chr6CNV40     167619368   167688151   68783     0.055   0.000   0.000   0.015
                                                                          
  chr7CNV41     64334979    64553672    218693    0.000   0.024   0.033   0.020
                                                                          
  chr7CNV42     76038186    76394983    356797    0.073   0.036   0.033   0.045
                                                                          
  chr7CNV43     81761377    81761849    472       0.000   0.000   0.050   0.015
                                                                          
  chr7CNV44     89187436    89247424    59988     0.036   0.012   0.000   0.015
                                                                          
  chr7CNV45     141420759   141433796   13037     0.036   0.060   0.067   0.056
                                                                          
  chr8CNV46     3775146     3776955     1809      0.055   0.036   0.050   0.045
                                                                          
  chr8CNV47     3987675     3990899     3224      0.073   0.000   0.000   0.020
                                                                          
  chr8CNV48     5583294     5591685     8391      0.018   0.036   0.000   0.020
                                                                          
  chr8CNV49     13643904    13652680    8776      0.036   0.012   0.000   0.015
                                                                          
  chr8CNV50     13657871    13680110    22239     0.182   0.012   0.000   0.056
                                                                          
  chr8CNV51     16307052    16309085    2033      0.018   0.048   0.000   0.025
                                                                          
  chr8CNV52     72378670    72378984    314       0.000   0.036   0.000   0.015
                                                                          
  chr8CNV53     137757412   137919630   162218    0.018   0.036   0.000   0.020
                                                                          
  chr9CNV54     507715      513495      5780      0.055   0.000   0.000   0.015
                                                                          
  chr9CNV55     581094      597738      16644     0.073   0.000   0.000   0.020
                                                                          
  chr9CNV56     5376384     5382199     5815      0.109   0.000   0.000   0.030
                                                                          
  chr9CNV57     9782326     9786116     3790      0.000   0.000   0.050   0.015
                                                                          
  chr9CNV58     11941204    12175185    233981    0.018   0.000   0.067   0.025
                                                                          
  chr10CNV59    20891019    20894574    3555      0.000   0.036   0.033   0.025
                                                                          
  chr10CNV60    45489854    47173619    1683765   0.200   0.157   0.050   0.136
                                                                          
  chr10CNV61    58186118    58188682    2564      0.036   0.024   0.000   0.020
                                                                          
  chr10CNV62    58583657    58603555    19898     0.000   0.000   0.067   0.020
                                                                          
  chr10CNV63    122759910   122774261   14351     0.127   0.000   0.000   0.035
                                                                          
  chr10CNV64    135116379   135219995   103616    0.073   0.060   0.017   0.051
                                                                          
  chr11CNV65    5858528     5889688     31160     0.000   0.000   0.050   0.015
                                                                          
  chr11CNV66    21145662    21170916    25254     0.109   0.012   0.000   0.035
                                                                          
  chr11CNV67    25574425    25580720    6295      0.036   0.012   0.000   0.015
                                                                          
  chr11CNV68    25662734    25676867    14133     0.127   0.012   0.000   0.040
                                                                          
  chr11CNV69    55139733    55201444    61711     0.036   0.120   0.267   0.141
                                                                          
  chr11CNV70    55217364    55346872    129508    0.036   0.000   0.000   0.010
                                                                          
  chr11CNV71    81182373    81192815    10442     0.018   0.120   0.117   0.091
                                                                          
  chr11CNV72    99154024    99156143    2119      0.000   0.012   0.050   0.020
                                                                          
  chr11CNV73    132499814   132509446   9632      0.000   0.036   0.000   0.015
                                                                          
  chr11CNV74    134154053   134211153   57100     0.018   0.036   0.000   0.020
                                                                          
  chr12CNV75    7888157     7982106     93949     0.018   0.000   0.050   0.020
                                                                          
  chr12CNV76    19364102    19442103    78001     0.000   0.024   0.017   0.015
                                                                          
  chr12CNV77    31180151    31298076    117925    0.036   0.060   0.017   0.040
                                                                          
  chr12CNV78    62269256    62415375    146119    0.036   0.012   0.033   0.025
                                                                          
  chr12CNV79    69162075    69162165    90        0.018   0.024   0.033   0.025
                                                                          
  chr12CNV80    126056007   126056525   518       0.055   0.000   0.017   0.020
                                                                          
  chr12CNV81    127794683   127830402   35719     0.000   0.012   0.017   0.010
                                                                          
  chr12CNV82    130297674   130314013   16339     0.000   0.024   0.017   0.015
                                                                          
  chr12CNV83    130368913   130378451   9538      0.036   0.024   0.033   0.030
                                                                          
  chr14CNV84    43576901    43584372    7471      0.000   0.000   0.133   0.040
                                                                          
  chr14CNV85    85358666    85376726    18060     0.018   0.024   0.000   0.015
                                                                          
  chr14CNV86    85540054    85557089    17035     0.000   0.036   0.000   0.015
                                                                          
  chr14CNV87    105997070   106237639   240569    0.073   0.157   0.067   0.106
                                                                          
  chr15CNV88    30298847    30301633    2786      0.073   0.012   0.033   0.035
                                                                          
  chr15CNV89    32530025    32587887    57862     0.127   0.072   0.067   0.086
                                                                          
  chr15CNV90    32724681    32757729    33048     0.000   0.036   0.000   0.015
                                                                          
  chr17CNV91    6047837     6061766     13929     0.036   0.012   0.000   0.015
                                                                          
  chr17CNV92    14988424    14998870    10446     0.000   0.000   0.117   0.035
                                                                          
  chr18CNV93    1915033     1964966     49933     0.018   0.036   0.000   0.020
                                                                          
  chr18CNV94    64898548    64905367    6819      0.018   0.036   0.333   0.121
                                                                          
  chr18CNV95    65360121    65362926    2805      0.000   0.036   0.017   0.020
                                                                          
  chr19CNV96    15641747    15690364    48617     0.091   0.000   0.000   0.025
                                                                          
  chr19CNV97    20423788    20473895    50107     0.109   0.084   0.033   0.076
                                                                          
  chr19CNV98    48066441    48387680    321239    0.127   0.084   0.133   0.111
                                                                          
  chr20CNV99    14729882    14770129    40247     0.036   0.036   0.000   0.025
                                                                          
  chr22CNV100   17270615    17376565    105950    0.036   0.000   0.033   0.020
                                                                          
  chr22CNV101   20718332    21554058    835726    0.218   0.253   0.167   0.217
                                                                          
  chr22CNV102   23994408    24239811    245403    0.055   0.060   0.033   0.051
                                                                          
                            Total       7805201                           
                            Average     76522                             
                            Median      19624                             
                            Minimum     90                                

The 102 CNV regions identified using the 197 DNA samples obtained from 3 ethnic groups.

![**Visualization of copy number regions identified in 15 randomly selected samples using Bead studio software**. Randomly selected individual samples are listed on the X-axis and chromosomes on the Y-axis. Each colored bar represents one CNV call. Colors indicate copy number; where dark red indicates copy \# 0, dark orange indicates copy \# 1, dark blue indicates copy \# 3, blue violet indicates copy \# 4+. The thickness of the band indicates the length of the CNV region.](1471-2164-11-357-1){#F1}

We compared our loci to those in the structural variation table in the University of California Santa Cruz\'s (UCSC) database <http://genome.ucsc.edu>. Figure [2](#F2){ref-type="fig"} shows an example on chromosome 22. Eighty-seven of the 102 loci that we identified overlapped with previously characterized CNVs, and 51/102 had been identified in more than one study. Of the 15 loci that had not been characterized previously, no obvious differences in size or prevalence were observed, suggesting that these are likely to be true CNVs and not the result of systematic error. In Figure [2](#F2){ref-type="fig"} we have superimposed our CNV values for a portion of chromosome 22 over UCSC database data. Divergence from the baseline indicates regions of CNV, while amplitude represents prevalence. Figure [2](#F2){ref-type="fig"} represents the overlap of our data (Illumina 550 + 650 K, Illumina 550 K, Illumina 650 K) at the top with previous reports at the bottom \[[@B7],[@B11]-[@B13],[@B21]-[@B25]\]. Lack of technical bias between Illumina 550 K and 650 K data is also shown since only the overlapping SNP set for the two platforms was used (Figure [2](#F2){ref-type="fig"}).

![**Comparison of chromosome 22 CNV regions identified using our 197 cell line samples compared with the results of previous studies in the UCSC genome browser**. The Illumina 550 + 650 K (all samples combined), Illumina 550 K (CA, CEPH, HCA populations) and Illumina 650 K (AA samples) results in the diagram are from the present study, where spikes in the data indicate changes in CNV values. The \"RefSeq Genes\" row shows the locations of known genes in the human genome. In the \"Structural Variation\" tracks, green color indicates duplications, red indicates deletions, blue indicates both deletion and duplication, black represents an inversion and gray could be a gain or loss. \"Conrad Dels\" in the diagram are deletions detected by the analysis of SNP genotypes using the HapMap Phase I data, release 16c.1, CEU and YRI samples \[[@B11]\]. \"Hinds Dels\" are deletions observed during haploid hybridization analysis in 24 unrelated individuals from the Polymorphism Discovery Resource, selected for a SNP LD study \[[@B12]\]. \"Iafrate CNVs\" are from BAC microarray analysis of a population of 55 individuals \[[@B21]\]. \"Locke CNVs\" are CNV regions identified using array CGH in 269 HapMap individuals \[[@B22]\]. \"McCarroll Dels\" are deletions from genotype analysis, performed with HapMap Phase I data, release 16a \[[@B13]\]. \"Redon CNVs\" are from SNP and BAC microarray analysis of HapMap Phase II data \[[@B7]\]. \"Sebat CNVs\" represents oligonucleotide microarray analysis performed with a population of 20 normal individuals \[[@B7]\]. \"Sharp CNVs\" represents putative CNV regions detected by BAC microarray analysis in a population of 47 individuals \[[@B24]\]. The \"Tuzun Fosmids\" row consists of fosmid mapping sites detected by mapping paired-end sequences from a human fosmid DNA library \[[@B25]\].](1471-2164-11-357-2){#F2}

We also had Affymetrix U133 Plus 2.0 expression array data for the same 197 lymphoblastoid cell lines in which we assayed CNV \[[@B18]\], which made it possible for us to quantify the expression of genes linked to CNVs. Forty one expression array probesets mapped close to (within 500 kb) or within the 102 CNV regions that we identified. Of those 41 probesets, only 7 were expressed (17% (7/41) when compared to the 28% of the 54,000 probesets across the entire genome that were expressed) in the lymphoblastoid cell lines, with an average expression value above \"100\" using GCRMA normalization data (Additional file [1](#S1){ref-type="supplementary-material"} Table S1).

Gemcitabine and AraC IC~50~value associations with CNVs
-------------------------------------------------------

To identify gene(s) that might contribute to variation in cytidine analog-induced cytotoxicity, we next analyzed associations between CNVs and IC~50~values for gemcitabine and AraC. We had previously performed gemcitabine and AraC cytotoxicity studies using the same cell lines, as described previously \[[@B18]\]. IC~50~values for both drugs were used as phenotypes for the association studies, and the analysis was adjusted for race and gender. The association studies with gemcitabine and AraC IC~50~value phenotypes resulted in the identification of 5 and 6 CNV regions, respectively, that showed associations with p-values \< 0.05 after 1000 permutations. Although these two drugs are similar in structure, we did not observe any common CNV regions that were significantly associated with IC~50~values for both gemcitabine and AraC. The annotation and association results for gemcitabine and AraC are listed in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, respectively.

###### 

Significant associations between gemcitabine IC50 values and CNV regions.

  CNV ID       Permutation P-value   Chromosome: Region          Number of SNPs   Length(bp)   SNP start-SNP end       Nearest Gene(s)
  ------------ --------------------- --------------------------- ---------------- ------------ ----------------------- -----------------
  chr9CNV58    0.027                 chr9:12005741-12098916      23               93176        rs10809674-rs12351590   *TYRP1*
                                                                                                                       
  chr1CNV5     0.031                 chr1:187795066-187809352    4                14287        rs382645-rs269747       *FAM5C*
                                                                                                                       
  chr14CNV87   0.036                 chr14:106047919-106066496   2                18578        rs4562969-rs10151262    *ADAM6*
                                                                                                                       
  chr11CNV74   0.042                 chr11:134154053-134211153   25               57101        rs1289444-rs2155304     *B3GAT1*
                                                                                                                       
  chr11CNV65   0.043                 chr11:5858528-5889688       12               31161        rs1377518-rs1453428     *OR52E4*

Association of CNV regions with the gemcitabine phenotype.

CNV validation using MLPA
-------------------------

To experimentally validate CNVs that were significantly associated with drug cytotoxicity, we tested the 11 CNVs with permutated p-values for association that were less than 0.05 using a high-throughput method designed to quantify genomic content, multiplex ligation-dependent probe amplification (MLPA). We were unable to amplify one CNV (chr14CNV87:106047919-106066496). When we compared MLPA to CNV values on a per-sample basis, 173/197 samples matched our original QuantiSNP CNV calls. Therefore, our original analysis had a zero false positive rate for all but two regions (1.23%), and the false negative rates ranged from 0% to 65% for the 10 regions that could be amplified (Additional file [1](#S1){ref-type="supplementary-material"} Table S2). The chr2CNV10 CNV, as shown in Table S2, had an exceptionally high false negative rate, and we cannot rule out the possibility that a SNP beneath the MLPA probe might be responsible.

Functional characterization
---------------------------

To further characterize CNV regions, we identified genes within 500 Kb of the 11 regions that were associated with gemcitabine or AraC IC~50~values. This relatively large region was chosen because previous studies have shown that *cis*-acting regulators can act over megabase distances \[[@B26],[@B27]\]. Two of the 5 regions that were significantly associated with gemcitabine cytotoxicity contained a gene within 500 Kb of the CNV. Both regions were on chromosome 11. One chromosome 11 region, 134154053-134158019, had 25 SNPs associated with the CNV. The nearest gene, *B3GAT1*, was 372016 bp distant from the CNV (Table [2](#T2){ref-type="table"}). The second chromosome 11 region, 5858528-5889688, had 12 SNPs associated with the CNV and the *OR52E4*gene overlapped this region.

In the case of AraC, one region (divided into 3 sub-regions, as shown in Table [3](#T3){ref-type="table"}) associated with AraC cytotoxicity was located on chromosome 22, with the nearest gene *LRP5L*(low density lipoprotein receptor-related protein 5-like), more than 3486 bases distant. Genes associated with chromosome 2 and 12 regions were *NPHP1*\[nephronophthisis 1 (juvenile)\], *PLEKHA5*(pleckstrin homology domain containing, family A member 5) and *GPR133*(G protein-coupled receptor 133), respectively. *NPHP1*and *PLEKHA5*overlapped the CNV regions, whereas *GPR133*was 179 Kb away from the CNV region associated with AraC. The region located on chromosome 1 overlapped the *KIF26B*gene and was 295 Kb away from a gene encoding a histone methyltransferase, *SMYD3*.

###### 

Significant associations between AraC IC50 values and CNV regions.

  CNV ID        Permutation P-value   Chromosome: Region          Number of SNPs   Length (bp)   SNP start-SNP end       Nearest Gene(s)
  ------------- --------------------- --------------------------- ---------------- ------------- ----------------------- -----------------
  chr22CNV102   0.013                 chr22:24092010-24128856     5                36847         rs713878-rs84486        *LRP5L*
                                                                                                                         
                0.028                 chr22:23999581-24091936     14               92356         rs6004527-rs713847      *LRP5L*
                                                                                                                         
                0.028                 chr22:24135224-24239811     30               104588        rs13057190-rs2780695    *LRP5L*
                                                                                                                         
  chr2CNV10     0.016                 chr2:89714801-89874746      9                159946        rs2847840-rs842164      *FLJ40330*
                                                                                                                         
  chr12CNV76    0.020                 chr12:19364102-19442103     16               78002         rs12825616-rs2565666    *PLEKHA5*
                                                                                                                         
  chr1CNV7      0.035                 chr1:243707190-243713984    6                6795          rs10737772-rs12121903   *SMYD3,KIF26B*
                                                                                                                         
  chr2CNV11     0.044                 chr2:110243431-110315618    11               72188         rs3789735-rs17463266    *NPHP1*
                                                                                                                         
  chr12CNV83    0.047                 chr12:130368913-130378451   5                9539          rs12319995-rs4759915    *GPR133*

Association of CNV regions with the AraC phenotype.

Since we had Affymetrix U133 Plus 2.0 mRNA expression array data for the same lymphoblastoid cell lines in which we had assayed CNV \[[@B18]\]; we determined average expression levels for all genes associated with the CNVs. Although there were no probesets associated with *ORE52E4*, we found that the average mRNA expression levels after GCRMA normalization for probesets linked with *B3GAT1, TYRP1, FAM5C, ADAM6, LRP5L, PLEKHA5, KIF26B, NPHP1, FLJ40330*, and *GPR133*were less than 10, suggesting either low or no expression of these genes in lymphoblastoid cells. Therefore, no further analysis was conducted with these candidates. However, one of the genes associated with AraC IC~50~had an average expression of 247 (*SMYD3*) in our cell lines and the expression of this gene was also associated with AraC IC~50~, with a p-value of 0.0027. The Chr1CNV7 association did not pass Bonferroni correction. However, the association study was a \"discovery\" study - to be followed by functional genomics validation. Hence, we selected the *SMYD3*candidate gene based on expression and possible biological relevance to cancer.

SMYD3 functional validation
---------------------------

It is known that knockdown of *SMYD3*inhibits cervical carcinoma cell growth and invasion \[[@B28]\] and that mutations in the 5\'-flanking region of *SMYD3*may represent a risk factor for human cancer \[[@B29]\]. It is also known that *SMYD3*plays crucial roles in HeLa cell proliferation and migration/invasion, so it has been suggested that it may be a useful therapeutic target in human cervical carcinomas \[[@B30]\]. As shown in Table [3](#T3){ref-type="table"}, a CNV region located on chromosome 1 close to the *SMYD3*gene (chr1CNV7) is associated with AraC IC~50~value, with a permutation p-value of 0.035. The chr1CNV7 deletion occurred in 3 samples, all from Caucasian subjects, so we also tested the association in only this ethnic group. Likelihood ratio testing of linear regression of AraC log IC~50~values against gender and storage time, with or without the relevant CNV values, gave a p-value of 0.019. In addition, analysis of IC~50~values with the chr1CNV7 region showed that deletion of this CNV region was associated with an increase in the IC~50~value for AraC (Table [4](#T4){ref-type="table"}). To confirm results obtained from the association study, we also performed specific siRNA knockdown of the *SMYD3*gene in human MIApaca-2 pancreatic cancer cells, followed by cytotoxicity studies. Down regulation of SMYD3 mRNA by siRNA desensitized the pancreatic cancer cells to AraC (P-value= 0.0011) when compared with cells transfected with negative control siRNA (Figure [3](#F3){ref-type="fig"}), a directional change consistent with the results of our CNV association study. Although, *SMYD3*did not show a significant association with gemcitabine cytotoxicity during the association study, we also performed functional studies with that drug. We found that knockdown of the *SMYD3*gene also made MIApaca-2 cells more resistant to gemcitabine (P-value = 0.0002) as shown in Figure [3](#F3){ref-type="fig"}. The Chr1CNV7 copy number was associated with gemcitabine IC50 values, (r-value = -0.01 and p-value = 0.804). While the p-value of association was insignificant, the directionality of the association was consistent with the results of the knockdown studies. In summary, knockdown of *SMYD3*, followed by cytotoxicity studies with both drugs, showed significant deviations, but the deviation was small for AraC when compared to that after gemcitabine treatment (Figure [3](#F3){ref-type="fig"}).

###### 

AraC IC50 value mean, median and standard deviations for copy number values = 1 (deletion) and copy number value = 2 (normal).

                  AraC IC~50~values (μmol)                
  --------------- -------------------------- ------------ -------------
  **CNV Value**   **Mean**                   **Median**   **Std Dev**
                                                          
  1               1.177                      1.092        0.486
  2               -0.017                     -0.180       0.998

Summary of IC~50~values for copy number = 1 and copy number = 2.

![**Functional characterization for the SMYD3 candidate gene with specific siRNA knockdown**. (A) Knockdown of the SMYD3 gene in human MIApaca-2 pancreatic cancer cells resulted in increased resistance to both AraC and gemcitabine as determined by MTS assay. SEM values for 3 independent experiments were so small that they are contained within the symbols. (B) Quantitative RT-PCR for *SMYD3*in MIApaca-2 cells. Error bars represent SEM values for three independent experiments.](1471-2164-11-357-3){#F3}

Finally, since the CNV close to the *SMYD3*gene was significantly associated with IC~50~, and since the functional validation studies of *SMYD3*agreed with the association study results, we expected that variation of mRNA expression for *SMYD3*in the cell lines might be significantly correlated with IC~50~. SMYD3 mRNA expression was significantly associated with IC~50~value, with a p-value of 0.028.

Discussion
==========

CNV can occur as a result of genomic rearrangements like deletion, duplication, inversion, and translocation. Features such as the presence of repetitive elements, size of the sequences, GC content, similarity and distance between the sequences play a critical role in determining susceptibility of regions to these rearrangement events \[[@B31]\]. Many methods have been used successfully to identify CNV regions across the genome. The high density of data from SNP platforms such as those of supplied by Illumina or Affymetrix has not only allowed us to perform genome-wide association studies to identify genotypes that are associated with a phenotype, but have also made it possible to quantify SNP alleles (log R ratios and B allele frequencies) for CNV. These log R ratios and B allele frequencies can be used to discover CNV by applying computational algorithms. However, despite advances in computational methods, the identification of intermediate sized CNVs (50 bp to 50 Kb) remains a challenge; since detection of CNVs is based on the density and spacing of probes on the platform.

In this study, we have used 550,000 SNP markers (Illumina 550 K Bead chip) to discover CNV in 197 human lymphoblastoid cell lines obtained from ethnically diverse populations. The average distance between markers on the Illumina 550 K chip is 5.8 kb, and the average size of CNVs identified in our cell lines was more than 76,000 bp, indicating that smaller CNV may be underrepresented in our study. The Illumina 550 K SNP chip was designed, in part, to interrogate gene rich regions \[[@B32]\]; which is an advantage with regard to a lower probability of our missing a gene-related CNV. We identified 775 CNVs in 102 regions with minor allele frequencies \> 1% (Table [1](#T1){ref-type="table"}). Variables such as array, coverage, intensity and CNV calling algorithms may all give different CNV calls. Therefore, we used previous copy number findings represented in the structural variation table in the UCSC database <http://genome.ucsc.edu> to compare with our CNVs and found that the vast majority of variant loci (87 of 102) were found in other publications, and 51/102 were represented in multiple studies. Although we did find agreement for many of our CNVs with previously reported variants, there were other CNV regions previously reported that were not identified in our study. This could be due to our stringent criteria for CNVs. It also could be due to the different platforms, methods and study populations used in different studies. In addition rare events are usually not reported.

It is known that variation in response to chemotherapy results from many factors, including gender, race, environmental factors and DNA sequence variation. DNA sequence variation may include both SNPs and CNV. Therefore, the presence of CNV is an important factor that may contribute to variation in response to chemotherapy. Specifically, the existence of CNV within or near a gene might result in differences in mRNA and protein expression. To identify possible pharmacogenomic candidate genes that might be affected by CNV, we tested the association of CNV with a drug response phenotype (IC~50~) for gemcitabine and AraC using a 197 lymphoblastoid cell line-based model system designed to make it possible to study common human genetic variation. Although tumor genome is critical for understanding response to therapy and disease pathophysiology, the germline genome is also critical, especially for drug response phenotypes. Obviously, we understand that these lymphoblastoid cell lines were EBV transformed from normal individuals, and that they were neither collected from cancer patients nor tumor tissues. Hence, we might miss some candidate genes that may be specific to cancer. However, lymphoblastoid cell lines have been shown by several groups, including ours, to be useful for identifying candidate genes or genetic variation associated with drug-induced cytotoxicity \[[@B18],[@B33]-[@B37]\]. Therefore, in this study we also used these lymphoblastoid cell lines to study the possible contribution of CNVs to variation in drug response. To begin the process of understanding how variation in copy number might affect drug response phenotypes for gemcitabine and AraC, we correlated 775 CNVs with IC~50~values in 197 lymphoblastoid cell lines. 11/102 regions were associated with gemcitabine and AraC IC~50~values (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). We then performed MLPA to compare with and to validate the in-silico QuantiSNP CNV calls.

Since we had Affymetrix U133 Plus 2.0 expression array data for the same lymphoblastoid cell lines \[[@B18]\]; we determined expression levels for genes surrounding the 11 CNV regions. The *B3GAT1, LRP5L, PLEKHA5, KIF26B, NPHP1, TYRP1, FAM5C, ADAM6, FLJ40330*, and *GPR133*genes had low expression. Only one CNV on chromosome 1 (chr1CNV7) had a gene (*SMYD3*) in close proximity that displayed high expression in the lymphoblastoid cell lines.

SMYD3, found on the q arm of chromosome 1, encodes an alternatively spliced transcript for 369 or 428 amino acids protein. Hamamoto et. al. first described SMYD3\'s histone methyltransferase activity with specificity for di- and tri- methylation of lys4 on Histone 3. SMYD3\'s histone methyltransferase activity results in transcription induction for at least 60 targets across the genome \[[@B38]\]. Enhanced expression of SMYD3 has been observed in numerous tumors including colorectal, hepatocellular \[[@B38]\] and breast cancer \[[@B39]\]. Overexpression experiments of SMYD3 have repeatedly shown to increase the rate of cell proliferation \[[@B38]-[@B40]\], while knockdown experiments result in decrease cell proliferation and cell migration while increasing apoptosis \[[@B28],[@B41]\]. Our studies indicated the association of the chr1CNV7 with AraC cytotoxicity as well as correlation with SMYD3 expression. Functional validations of our results were performed with knockdown of the *SMYD3*gene in pancreatic cancer cell lines. Knockdown made the cells more resistant to AraC, confirming the association study results, and also made them resistant to gemcitabine. Our results suggest that joining association studies with functional validation experiments may help to identify biomarkers for disease or response to therapy.

Conclusions
===========

We took the advantage of genome-wide SNP data obtained with 550 K Illumina Bead Chips to identify CNV regions across the genome in 197 lymphoblastoid cell lines. Association studies with gemcitabine and AraC cytotoxicity phenotypes identified CNV regions that might be associated with cytotoxicity for these two drugs. In this study we investigated the role of CNVs together with expression of neighboring genes (*B3GAT1, LRP5L, PLEKHA5, KIF26B, TYRP1, FAM5C, ADAM6, FLJ40330, NPHP1, OR52E4, GPR133*and *SMYD3*) with drug response phenotypes. Analysis in lymphoblastoid cell lines and functional validation in cancer cell lines suggest the probable role of SMYD3 to AraC and gemcitabine drug response phenotype. The current study provides additional information with regard to the contribution of CNVs to variation in drug response for two important antineoplastic drugs and indicates that the assay of CNV should be included in pharmacogenomic studies.
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